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or Subsequent Allogeneic Transplantation
Meirav Kedmi,1 Igor B. Resnick,1 Liliane Dray,1 Memet Aker,2 Simcha Samuel,1
Benjamin Gesundheit,1 Shimon Slavin,1 Reuven Or,1 Michael Y. Shapira1The failure of allogeneic stem cell transplant (allo-SCT) is cumbersome. We analyzed our experience in
a second allo-SCT. Between the years 1981 and 2007, 144 patients underwent 2 or more allo-SCT. The first
to second transplant interval ranged from 18 days to 13.25 years (median 98 days). The most frequent
indications for the second SCTwere activity of the basic disease (78), rejection (37), and engraftment failure
(25). Twenty-nine of the 144 (20%) patients transplanted survived more then a year with treatment-related
mortality of 45.5% as the leading cause of death. Interestingly, despite the low rate of graft-versus-host
disease (GVHD) prophylaxis used, only 51 and 16 of the patients developed acute and chronic GVHD
(aGVHD, cGVHD), respectively. Factors indicating higher likelihood for survival were nonmalignant disease,
a nonrelapse indication for the second SCT, full HLA-matching, and the use of reduced-intensity conditioning
(RIC). Age at transplantation, time interval between transplants, the development of GVHD, conditioning
regimen, GVHD prophylaxis, or graft source were not shown to influence the prognosis. With a median
follow-up of 4.5 years, 25 patients (17.2%) are alive, and 18 are disease-free.We conclude that although toxic,
a second allo-SCT can lead to long-term survival.
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Patients who undergo allogeneic bone-marrow or
blood stem cell transplantation (allo-SCT) may suffer
from graft rejection, engraftment failure, or relapse of
their primary disease. The only therapeutic option
may be second allo-SCT. Very little is known about
the outcome of those patients. Acute leukemia
patients, who relapse after first allo-SCT, were shown
to have poor outcome in the second [1]. There is, how-
ever, some evidence that the outcome of the second
allo-SCT is better if the disease burden is low [2] or
if the first SCT was autologous [3]. Kobayashi et al.
[4] found that some acute myelogenous leukemia1Department of Bone Marrow Transplantation & Cancer
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6/j.bbmt.2009.01.009(AML) patients achieved prolonged remission after
allogeneic immunotherapy-based interventions, but
these procedures carried a high risk [4]. In children
with AML there seems to be better results, but there
are not much data [5]. Greater success has been
reported with chronic myelogenous leukemia (CML)
patients undergoing repeated allo-SCT [6].
In nonmalignant diseases, however, the data is
even vaguer. There is 1 case report in the literature
about a severe aplastic anemia (SAA) patient who
underwent 3 allo-SCTs because of engraftment fail-
ure, the last of which was successful [7]. Additionally,
we found 3 other case reports about patients with
genetic diseases undergoing SCT [8-10]; in each of
these reports, 1 of the patients underwent a successful
second or higher allo-SCT. Recently, Ayas et al. [11]
documented their experience in 4 patients with
Fanconi’s anemiawhowere reconditionedwith antithy-
mocyte globulin (ATG).
Because the major advantage of allo-SCT is
because of the graft-versus-leukemia (GVL) effect
mediated by alloreactive donor lymphocytes adminis-
tered at the time of transplant [12] or donor leukocyte
infusions (DLI) administered posttransplantation
[13,14], availability of reduced-intensity conditioning
(RIC) [15], lower dose, or earlier withdrawal of post-
transplant immunosuppression [16], more aggressive483
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alloreactivity induced by another donor may improve
the efficacy of a subsequent transplant procedure.
To achieve better understanding of the course of
the second allo-SCT, to have better future selection
of the target patient population, and to provide
patients with enough data to get an informed consent,
we analyzed the outcome of all the patients who under-
went 2 or more allo-SCTs in our institution.METHODS
Patients’ Characteristics
Between the years 1981 and 2007, 1533 allo-SCTs
were performed in our department. One hundred
forty-four patients (92 males) underwent more than
1 allo-SCT (10 underwent 3 allo-SCTs). The median
age at the second SCT was 20.7 years, with a range of
8 months to 68.4 years. The indications for the
first allo-SCT were acute leukemia/myelodysplastic
syndromes (MDS) (92), chronic leukemia (17), lym-
phoma (3), other malignancies (3) and nonmalignant
(29) (Table 1).
Conditioning Regimen and Graft-versus-Host
Disease (GVHD) Prophylaxis
GVHD prophylaxis (when given) consisted of
short-term cyclosporine (CsA) starting on day 24
or 21.
In some of the patients with partially matched
donors (2-3 HLA mismatches), T cell depletion was
done using positive stem cell selection (CD34 immu-
nomagnetic beads (Miltenyi biotec, Germany) or
Campath-1G and later on alemtuzumab introducedTable 1. Disease Distribution among Patients Who




Malignant Acute myelogenous leukemia/myelodysplastic
syndrome
70
Acute lympoblastic leukemia 22
Chronic myelogenous leukemia 17
Multiple myeloma 1
Non-Hodgkin lymphoma 3
Renal cell carcinoma 1
Testicular carcinoma 1
Nonmalignant Severe aplastic anemia 9
Thalassemia major 5
Severe combined immunodeficiency 4
Adrenoleukodystrophy 2
Leukocyte adhesion deficiency 1
Chediak Higashi syndrome 1
Multiple sclerosis 1
Fanconi’s anemia 1
Hyper IgM syndrome 1
Wolman’s disease 1
Wiskott Aldrich syndrome 1
Kostmann’s syndrome 1
Metachromatic leukodystrophy 1
SCT indicates stem cell transplantation.‘‘in the bag’’ (mabcampath, Bayer Schering pharma,
UK).
Donors
Donors were fully matched siblings (n 5 83),
matched unrelated donors (MUD, n5 8), and 1-locus
mismatched unrelated donors (n 5 2). Mismatched
family member donors with 2-3 mismatches were
used in 51 transplants. Peripheral blood stem cells
(PBSCs) (n 5 79) were mobilized by granulocyte-
colony stimulating factor (G-CSF) (Neupogen) and
stem cells were collected on days 5 and 6). Bone
marrow aspiration was done under anesthesia using
standard aspiration needles (n 5 65).
Supportive Care
Prior to transplantation, all patients received tri-
methoprim/sulfamethoxazole until day 22, acyclovir
from the initiation of therapy at least until day 1120,
and allopurinol until day 21. Trimethoprim/sulfame-
thoxazole was reinstituted after recovery from neutro-
penia for 6 months. Febrile neutropenia was treated
according to the hospital’s protocols.
Starting on day 28, cytomegalovirus (CMV) was
monitored with a DNA-polymerase charin reaction
(PCR) test or pp65 antigenemia on a weekly basis.
CMV reactivation indicated replacing acyclovir with
ganciclovir until a minimum of 2 negative tests were
obtained. Patients were treated with reverse isolation
HEPA-filtered rooms, and received a regular diet.
Additional supportive measures, such as parenteral
nutrition and blood component transfusion, were
administered as necessary.
Acute and chronic GVHD (aGVHD, cGVHD)
were graded according to the International Bone
Marrow Transplantation Registry (IBMTR) severity
indices [11,18]. Immediately upon the appearance of
signs and symptoms of GVHD, i.v. methylpredniso-
lone (2 mg/kg) and CSA were administered.
To assess engraftment, degree of chimerism,
minimal residual disease, and early relapse, patients
weremonitored at regular intervals by cytogenetic anal-
ysis, by male/female amelogenine gene PCR bands
[12,19], and by variable-number tandem repeat
(VNTR)-PCRassay [13,20]. All patients or their guard-
ians signed an informed consent prior to the procedure.
Definitions, Statistics
Data were collected by comprehensive data man-
agement and chart review. A second transplant was
defined as any conditioning treatment followed by
infusion of donor bone marrow or PBSCs (thus
excluding treatment not followed by stem cells or
stem cells not proceeded by conditioning). Major out-
comes of attention were treatment-related morbidity
and mortality (TRM), survival, nonrelapse mortality
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incidence/severity of GVHD. Preengraftment death
excluded from aGVHD analysis; death before day 100
excluded from cGVHD analysis. Engraftment failure
was defined as peripheral blood aplasia and marrow
hypoplasia .21 days posttransplant, with no evidence
of donor markers revealed by cytogenetic and molecu-
lar techniques, whereas graft rejection was defined as
peripheral blood aplasia and marrow hypoplasia .21
days posttransplant, with evidence of donor markers
that appeared and then disappeared. Overall survival
(OS) was defined as time from the day of transplanta-
tion to death from any cause, or last follow-up. Relapse
was defined as the recurrence of the malignancy,
after the initial achievement of complete remission.
Disease-free survival (DFS) was defined as time from
the day of transplant until relapse or death from any
cause. In patients who did not achieve remission of
the disease post transplant, day 0 was considered for
DFS analysis as the day of relapse. Treatment-related
morbidity and TRMwas defined as morbidity or mor-
tality because of any cause other than disease progres-
sion within 100 days of transplantation. NRM was
defined as mortality because of any cause other than
disease progression within 1 year of transplantation.
Data were analyzed using Microsoft excel and
Medcalc (Medcalc Inc., Belgium).The probabilities
of OS and DFS were plotted using the Kaplan-Meier
method. The significance was estimated by log-rank
test and logistic regression analysis. Chi-square was
used to analyze some survival predictorsRESULTS
One hundred forty-four patients underwent 298
allogeneic transplant procedures.
The first to second SCT time interval ranged
between 18 days and 13.25 years (median 89 days).
The most frequent indications for the second SCT
were relapse/resistant basic disease (79), rejection
(37), and engraftment failure (25) (Table 2).Engraftment
Neutrophils and platelet engraftment at the second
transplant occurred in 97 (67%) and 48 patients (33%),
respectively. The median time to white blood cellTable 2. Indications for the Second SCT
Number of Patients
Relapse/resistant basic disease 78
Rejection 37
Engraftment failure 25
Donor type leukemia 1
Allogeneic SAA (graft versus graft) 1
SCT indicates stem cell transplant, SAA, severe aplastic anemia.(WBC) (.1  109/L) and absolute neutrophil count
(ANC) (.0.5  109/L) engraftment was 15 days
(range: 1-135) and 17 days (range: 1-125), respectively.
The range of time to platelets recovery was 1-131 days
(median: 14 days). In the subgroup of patients that
underwent 3 allogeneic SCTs, there was no difference
in the rate or time of engraftment within transplants.
The median time for WBC and ANC engraftment
was 20 and 16 days and 21, and 18 days for the second
and third SCT, respectively (all nonsignificant). Like-
wise, the median time for platelets engraftment was 31,
and 56 days for the second and thrid SCT, respectively
(nonsignificant).
Incidence and Severity of GVHD
Fifty-one of the 97 patients who engrafted (51%)
developed aGVHD, with a median onset time at 23
days. Ten patients had grade I aGVHD, whereas 41
had grade II-IV. With a median time of 101 days 16
of 55 (29.1%) of the evaluable patients developed
cGVHD; most of them evolved from aGVHD. Seven
patients had severe cGVHD, 2 had moderate, and the
rest had mild cGVHD.
NRM
Eighty-four patients (58%) died within the first
100 days of second transplant. Eighteen (12.5%) died
of relapse/progression of their basic disease and 66
(45.5%) from transplant-related complications. Among
them, 28 died of different infections, 15 of treatment-
related organ toxicities, 8 of engraftment failure, 5 of
rejection, 9 from aGVHD, and 1 patient committed
suicide.
Transplant Outcome
Twenty-nine patients (20%) survived at least a year
after the second procedure (Figure 1). The median
survival from the second SCT was 70 days (range: 1
day to 23.7 years). Median DFS was 59 days (range:
1 day to 23.7 years). Twenty-five patients (17.2%)
are alive at the time of this report with a median
follow-up of 4.5 years; of them 18 are disease-free.
Ten patients underwent 3 allogeneic SCTs, of these,
3 survived at least 1 year from the third SCT. Four
patients are alive at the time of this report (1 with
7 months follow-up), all are disease free. Causes of
death were relapse (3), infection (2), and cGVHD (1).
The factors that were associated with higher
chance of survival were: basic disease (malignant versus
nonmalignant), indication for the second SCT (relapse
versus nonrelapse), donor matching (full match versus
mismatched), and conditioning regimen (RIC versus
myeloablative).
Of the 29 patients who were transplanted for non-
malignant cause, 15 were alive a year from the second
SCT, whereas among the patients suffering from
Figure 3. (A) Survival according to the indication for the second SCT.
Patients who were transplanted because of persistent/relapse of their
basic disease survived significantly less than those who were trans-
planted for other reasons. (B) Survival according to donor matching in
the second SCT—patients who had the second transplant from
a matched donor survived significantly more then those who were
transplanted from a mismatched donor.
Figure 1. OS and DFS of all the 144 patients who underwent more
than 1 allogeneic SCT. Most patients surviving the second procedure
are in continuous remission.
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(Figure 2; P5.0009).
Seventy-nine patients had the second transplant
because of relapse or refractory disease, and 65 because
of other indications; the number of survivors at 1 year
was 8 and 21, respectively (Figure 3A; P5.013).
Only 4 of 53 patients who were transplanted from
a mismatched donor survived a year. In contrast to
that, 25 of 91 patients (27.5%) who were transplanted
from a full-matched donor were alive at 1 year
(Figure 3B; P5.029).
RIC regimen in the second SCT (Figure 4) was
associated with higher probability of survival at 1
year (23 of 80) compared with myeloablative regimen
(6 of 64) (P5.03).Figure 2. OS of patients according to basic disease. It is clear that
patients who underwent the second allogeneic SCT because of a nonma-
lignant condition survived better then patients with malignant diseases.The factors that were not significant as predictors
of survival at 1 year from the second transplant were
age, the development of aGVHD, chemotherapy ver-
sus radiotherapy-based conditioning, stem cell originFigure 4. OS from second SCT according to conditioning regimen.
Patients who underwent RIC survived significantly better then those
who underwent myeloablative conditioning.
Biol Blood Marrow Transplant 15:483-489, 2009 487Second Allogeneic SCT(bone marrow [BM] versus PBSC), the interval
between SCTs and the use of GVHD prophylaxis
(pharmacologic or T cell depletion).
Subgroup analysis of the patients with malignant
diseases (n5 115), demonstrated that the only predic-
tor of 1-year survival was donor matching. Patients
who were transplanted from a fully matched donor
survived significantly more than those that were not
(P5.034). All the other parameters that were checked
(including age at transplantation, time between trans-
plants, conditioning regimen, second transplant’s indi-
cation, GVHD prophylaxis, aGVHD occurrence, and
cells’ source), did not significantly differ between the
groups.DISCUSSION
The failure of allo-SCT is mostly fatal. For these
patients, the only curative alternative is to consider
another allo-SCT. So far, there is very little informa-
tion in the literature regarding such a cohort of
patients. To develop better understanding of the fate
of patients failing allo-SCT and have better idea about
the indications and future selection of the target
patient population in need, to provide justification
for consideration of a second or third transplant proce-
dure, and to offer patients enough data to get an
informed consent, we retrospectively analyzed the
medical records of all patients that underwent more
than 1 allo-SCT procedure for any indication in our
center between the years 1981 and 2007. We then
compared and analyzed the data of patients who sur-
vived at least a year after second allo-SCT to those
who did not survive, using different parameters.
The most significant factor that we found as
a predictor of prolonged survival was the basic disease
for which the first allo-SCT was performed. More
patients with nonmalignant diseases (Figure 2) sur-
vived compared with patients with malignant diseases.
To date, most of the data in the literature deals with
patients who underwent 2 allo-SCTs for malignant
diseases, mostly AML, acute lymphoblastic leukemia
(ALL), and CML. Frassoni et al. [1] analyzed retro-
spectively the European Blood and Marrow Trans-
plant (EBMT) registry for the outcome of 117
patients with either AML or ALL, who relapsed after
allogeneic SCT. Nine of the 117 patients (7.7%) un-
derwent another allo-SCT; of them, only 1 had pro-
longed survival (11%). Radich et al. [6] published the
Seattle experience with a second allo-SCT. Seventy-
seven patients with AML, ALL, or CML, aged 2-51
years, who relapsed after allogeneic transplant with
TBI containing regimens, were transplanted again
from the same donor with intensive chemotherapy
conditioning. As may be expected, veno-occlusive dis-
ease (VOD) was the most common cause of severetreatment-related toxicity and TRM. TRM was high
(36%), and the risk for relapse was even higher (relapse
probability was 70%). The risk of relapse was inversely
related with GVHD. DFS rate was 14% with different
DFS rates for ALL, AML, and CML (8%, 10%, and
25%, respectively). The authors demonstrated that
young patients and CML patients were the most likely
to succeed in a second SCT. In the subgroup analysis
we did for patients with malignant diseases, we found
the only predictor for survival was full donor match-
ing; all the other parameters were not significantly dif-
ferent between the groups.
There is no comprehensive data in the literature
regarding second allo-SCT in genetic/nonmalignant
diseases. There are only reports on 3 patients with
chronicgranulomatousdisease (CGD),Wiskott-Aldrich
syndrome, or Diamond-Blakfan anemia undergoing
SCT, in which 1 of the reported patients underwent
more than 1 allogeneic SCT [8-10]. We had 29 patients
with different nonmalignant diseases (Table 1) who un-
derwent 2 allo-SCTs. Of them, 15 survived at least a
year after the procedure. This finding might reflect
the greater success of allo-SCT reported in genetic
diseases [21].
In patients who were transplanted because of
relapse, the survival rates were considerably lower.
Patients with resistant malignancies who did not re-
spond to chemotherapy had lower chances to respond
to a second transplant procedure. However, 8 of 70
(11.4%) of patients who had a second transplant did
benefit a long-term DFS. Hosing et al. [2] also found
that patients with AML/MDS have better outcome
in a second transplant if they start it with low disease
burden (absence or \5% blasts in the peripheral
blood). Despite that, we found 14 patients with
resistant malignant diseases (AML, ALL, and CML)
surviving longer than a year after second SCT.
Another interesting finding in our analysis was that
the use of RIC was associated with significantly better
outcome compared with myeloablative conditioning.
One would be predisposed to use myeloablative condi-
tioning in many types of transplant failure (eg, relapse,
rejection, engraftment failure, etc.). However, in view
of the high incidence of transplant associated toxicity
and TRM expected in second allo-SCT [6], which
may be linked to cumulative damage because of past
exposure to high doses of chemoradiotherapy on the
1 hand, and higher resistance to future anticancer che-
motherapy, treating physicians should prepare to
choose RIC for the second SCT.
In our cohort, HLA matching was also an impor-
tant factor predicting prolonged survival both in the
whole patient group and in the subgroup of patients
with malignant diseases. Patients who underwent sec-
ond allo-SCT from a matched donor (either family or
MUD) survived more than those who received the
graft from a haploidentical or mismatched donor.
488 Biol Blood Marrow Transplant 15:483-489, 2009M. Kedmi et al.This is not surprising if we consider the higher TRM
in haploidentical and mismatched transplantations
[22], and that the most common cause of death in
our cohort was indeed TRM.
Among the factors that did not have an effect on
survival the most surprising 1 was the age at second
SCT. As mentioned before [5], there is some evidence
that children and young adults are more likely to
succeed in second allo-SCT. Chewning et al. [23]
recently reported 16 patients who underwent second
allo-SCT because of graft failure. They found that
the outcome was superior in patients who were youn-
ger than 20 years. Eapen at al. [24] also reported that
patients younger than 20 are more likely to succeed
in second allo-SCT. Platzbecker et al. [25] reported
that patients younger than 50 years and those with
graft failure as the etiology for second transplant did
better. Our findings were not limited by the number
of patients, as 67 of 144 patients in our group were
children and young adults under the age of 18 years
at the time of the second transplant and the median
age of the whole group was 20.7 years. Moreover, we
might have had a selection bias, because reduced
performance status in this clinical situation is more
common in older patients who were accordingly not
offered a second SCT. Therefore, our interpretations
might not be relevant to older patients.
It would be reasonable to assume that patients who
maintained remission longer after first allo-SCT will
be more likely to succeed in the second procedure.
Indeed, the time interval between transplants was
previously reported as an important factor predicting
survival after second transplant [24]. We could not
reproduce such an effect in our analysis.
Another interesting finding was that the use of
GVHD prophylaxis or T cell depletion did not affect
survival. This finding is further supported by the lack
of impact of aGVHD on survival. The expected
GVL (especially in patients with no relapse after the
second SCT)may have been counterbalanced by trans-
plant-related toxicity.
A remarkable group that deserves a separate
discussion was the 10 patients who underwent 3 allo-
SCT procedures. Of these patients (median ages 12.4
and 13.3 years at the second and third SCT, respec-
tively), including 7 with malignant diseases, 3 patients
are long-term survivors, and all are disease free. The
repeated conditioning procedures did not seem to
harm the engraftment processes and the rate and
time to engraftment was the same in the first, second,
and thrid SCTs.
Despite the long period of time that is represented
in our cohort with all its disadvantages in terms of dif-
ferences in supportive care quality, conditioning regi-
mens, and immunosuppressive therapy, we believe
there are some important conclusions that can be
made.Our data supports the notion that a second allo-
SCT should be seriously considered especially for
patients with nonmalignant disorders, but also for
a selected group of patients with malignant diseases
failing the first allogeneic SCT, especially if they
have responded to conventional chemotherapy tomin-
imize the risk of early relapse, or if transplant failure
occurred while in remission. Some patients with
refractory disease may even benefit from a third trans-
plant procedure and remain disease free with good
quality of life. A larger number of patients and longer
observations are needed to confirm the benefit and
cost-effectiveness of allo-SCT for patients who failed
the first transplant procedure because availability of
RIC supported by posttransplant immunotherapy
may increase the probability of a successful second,
and in rare cases, even a third transplant procedure.ACKNOWLEDGMENTS
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